Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Invasive lobular carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Invasive lobular carcinoma. Displaying page 1 of 1.
    EudraCT Number: 2019-004942-14 Sponsor Protocol Number: IJB-LOB-2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
    Medical condition: ER-positive/HER2-negative invasive lobular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073096 Invasive lobular breast carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001428-23 Sponsor Protocol Number: M17GEL Start Date*: 2017-09-29
    Sponsor Name:NKI-AVL
    Full Title: AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024745 Lobular breast carcinoma invasive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007740-10 Sponsor Protocol Number: TAM-01 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN)
    Medical condition: chemoprevention of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021587-15 Sponsor Protocol Number: ICORG10-04NSABP-B46I Start Date*: 2010-09-08
    Sponsor Name:ICORG
    Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003047-24 Sponsor Protocol Number: CA163-100 Start Date*: 2007-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Not Overexpressin...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) GB (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000134-34 Sponsor Protocol Number: TEAM(B115UCS2019) Start Date*: 2021-05-24
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
    Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006259-12 Sponsor Protocol Number: 1814 Start Date*: 2012-09-03
    Sponsor Name:Jules Bordet Institute
    Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res...
    Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004822-19 Sponsor Protocol Number: ICORG 05-11/NSABP B-38 Start Date*: 2006-02-15
    Sponsor Name:ICORG the all Ireland Co-operative Oncology Research Group
    Full Title: A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphami...
    Medical condition: Early stage node positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003998-17 Sponsor Protocol Number: ONCOGHdC2015-01 Start Date*: 2017-02-16
    Sponsor Name:Grand Hôpital de Charleroi
    Full Title: A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
    Medical condition: patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022902-41 Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g Start Date*: 2011-09-26
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa...
    Medical condition: Patients with operable HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IE (Completed) SE (Completed) DK (Completed) SI (Completed) NL (Completed) BE (Completed) SK (Completed) AT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000189-45 Sponsor Protocol Number: Start Date*: 2018-03-26
    Sponsor Name:University of Padova
    Full Title: Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-l1 antibody Avelumab: A phase III randomized trial
    Medical condition: High risk triple negative (ER negative, PR negative, HER2 negative) breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002488-88 Sponsor Protocol Number: GS-US-321-0105 Start Date*: 2013-07-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Advanced Liver Fibrosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002162-21 Sponsor Protocol Number: JECF-VITD-2011-01 Start Date*: 2012-04-24
    Sponsor Name:José Esteban Castelao Fernández
    Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer.
    Medical condition: Women at high risk of developing breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005127-29 Sponsor Protocol Number: TAX_GMA_302 Start Date*: 2001-05-21
    Sponsor Name:SANOFI-AVENTIS
    Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI...
    Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 17:31:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA